Metal ions often play critical roles in protein structure and function. Engineered metal-binding sites in peptides and proteins have been widely used to enhance structural integrity, stabilize biologically active conformations, and confer novel enzymatic activities (1-3). Biochemical and structural analyses of transition-metal coordination by proteins and peptides have traditionally focused on zinc, copper, manganese, and iron because of their roles in important biological processes (4-7). Other transition metals not found in natural proteins have coordination, isotopic, and chemical properties that make them attractive for peptide and protein engineering. Rhenium (Re) and technetium (Tc) are group VIIB transition metals that share similar coordination geometries and form stable complexes with amine and amide nitrogens, carboxylate oxygens, and thiolate and thioether sulfurs, with a strong preference for thiolate sulfurs (8). Radioactive isotopes of Re and Tc have significant medical applications because of the nature of their associated radiation and physical half-life properties.
Metal ions often play critical roles in protein structure and function. Engineered metal-binding sites in peptides and proteins have been widely used to enhance structural integrity, stabilize biologically active conformations, and confer novel enzymatic activities (1) (2) (3) . Biochemical and structural analyses of transition-metal coordination by proteins and peptides have traditionally focused on zinc, copper, manganese, and iron because of their roles in important biological processes (4) (5) (6) (7) . Other transition metals not found in natural proteins have coordination, isotopic, and chemical properties that make them attractive for peptide and protein engineering. Rhenium (Re) and technetium (Tc) are group VIIB transition metals that share similar coordination geometries and form stable complexes with amine and amide nitrogens, carboxylate oxygens, and thiolate and thioether sulfurs, with a strong preference for thiolate sulfurs (8) . Radioactive isotopes of Re and Tc have significant medical applications because of the nature of their associated radiation and physical half-life properties.
The synthesis and characterization of radiolabeled antibodies, peptides, and steroid hormones as in vivo tumor-imaging and therapeutic agents is an active area of cancer research today. These molecules specifically target tumor cells by virtue of their high specificities for receptors and antigens present on the surfaces of these cells. In one commonly used approach, metallic radionuclides such as 186 Re, 188 Re, and 99m Tc are appended to the tumor-targeting molecule through bifunctional chelate groups that consist of a metal chelate and an activatable crosslinker (9) (10) (11) . The resulting radiolabeled proteins, peptides, and small molecules are decorated with one or more chelating groups. The presence of bulky metal-chelating groups and their associated crosslinkers may affect receptor affinity and biodistribution in vivo (12, 13 ). An alternative approach to the design of radiolabeled tumor-imaging and therapeutic agents involves incorporating the metal directly into the molecule's structure (14) (15) (16) . Metal centers with defined coordination geometries can in this way provide a foundation for the construction of stable molecular structures that have high affinities for specific receptors or antigenic sites. Protein, peptide, and small-molecule structures can be designed to use metal coordination to reduce conformational freedom, stabilize active conformations, or mimic native conformations.
␣-Melanocyte stimulating hormone (␣-MSH) is a tridecapeptide [Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-GlyLys-Pro-Val-NH 2 ] that regulates skin pigmentation in most vertebrates (17) . The core ␣-MSH sequence His-Phe-Arg-Trp, conserved in a number of species, is sufficient for receptor recognition (17) . The presence of ␣-MSH receptors on both murine and human melanoma cells (18, 19) suggests that ␣-MSH analogs could be developed into targeted melanomaimaging or therapeutic agents. Several analogs of ␣-MSH have been radiolabeled either with halogens or with transitionmetal radionuclides coordinated by bifunctional chelates (20) (21) (22) (23) Tc-radiolabeled ␣-MSH analogs in which metal coordination was an integral part of the molecules' structure. It was hypothesized that cyclic ␣-MSH analogs, engineered to incorporate radionuclides directly into their structures, would display exceptional stability, biodistribution, and tumor-targeting properties. Rheniumbound ␣-MSH analogs were synthesized and characterized to determine whether different metal-incorporation strategies resulted in molecules with different structural stabilities and bioactivities. Incorporation of Re into an initial ␣-MSH analog resulted in decreased stability and receptor affinity. 
MATERIALS AND METHODS

Synthesis and Purification of Peptide-Metal Complexes.
The peptides NAc-Cys-Glu-His-D-Phe-Arg-Trp-Cys-Lys-ProVal-NH 2 (24) and NAc-Cys-Cys-Glu-His-D-Phe-Arg-Trp-CysLys-Pro-Val-NH 2 were synthesized by using standard fluorenylmethoxycarbonyl (Fmoc) chemistry. The bombesin analog Trp-Ala-Val-Gly-His-Leu-Met-NH 2 was purchased from Sigma. ReMSH was synthesized by using the exchange complex ReOCl 3 (Me 2 S)(OPPh 3 ) (25, 26) by incubation of 1:1 peptide͞exchange complex in 62% MeOH, pH ϭ 8-9 at 65-70°C for 1 hr. ReCCMSH was synthesized by using the exchange complex Re-glucoheptonate by incubation of 1:1 peptide͞exchange complex in 62% MeOH, pH ϭ 8-9 at 65-70°C for 1 hr. The Re-peptide complexes were purified by C 18 reverse-phase HPLC. ReMSH was further purified by normal-phase HPLC with a polysulfoethyl aspartamide column from Poly LC (Columbia, MD). Both complexes underwent Ellman's analysis to test for the presence of free sulfhydryl groups (27) . Mass spectrum analyses were performed by electrospray ionization mass spectroscopy at Mallinckrodt for ReCCMSH and by fast atom bombardment-mass spectroscopy for ReMSH at the University of Kansas (Lawrence, KS) mass spectrometry facility. Re complexes, 500 l of generator eluent was added to a tube containing 50 mg of sodium glucoheptonate and 10 mg of SnCl 2 ⅐2H 2 O dissolved in 200 l of N 2 -purged 5% EDTA and heated at 70-80°C for 30 min. Fifty microliters of a 1 mg͞ml peptide solution was then added, the pH was adjusted to 7-8 with 0.5 M NaOH, and the mixture was allowed to incubate for 90 min at 70-80°C. Syntheses of 99m Tc-labeled peptides differed only in that they were carried out at 25°C by using 1͞10 the concentration of SnCl 2 ⅐2H 2 O. Radiolabeled complexes were analyzed by coinjection on a C 18 reverse-phase HPLC column, and in all cases were found to coelute with the previously characterized nonradioactive standards. Tracerlevel stability tests were performed by diluting the tracer-level reaction mix 1:2 into a 20 mM solution of cysteine or diethylenetriaminepentaacetic acid (DTPA) at t ϭ 0.
NMR Data Collection and Processing. NMR data were collected on a 500-MHz Bruker AMX or DMX spectrometer and processed on a Silicon Graphics (Mountain View, CA) XZ4000 workstation with the SYBYL program (Tripos Associates, St. Louis). The 1 H data were collected in 9:1 H 2 O͞D 2 O at concentrations ranging from 4 to 10 mg͞ml. All spectra were recorded by using the time-proportional phase incrementation (TPPI) method. In most cases, the spectral width was 6,000 Hz.
Typically the data set size was 2,048 (t 2 ) ϫ 256 (t 1 ) blocks with between 16 and 64 scans per FID (free induction decay). Two-dimensional spectra for the peptide-metal complexes were collected at 298 K.
Receptor-Binding Assay. Quantitative receptor-binding assays were carried out following a previously described method (28, 29) . Cells were seeded at a density of 5 ϫ 10 5 cells per well in 24-well tissue culture plates and exposed to various concentrations of peptides in 0.5 ml of binding media (25 mM Hepes͞NaOH, pH 7.4͞0.2% BSA͞0.3 mM 1, 10-phenanthroline͞Ϸ100,000 cpm of 125 ]-␣-MSH in 100 l of saline solution subcutaneously between the scapulae 30 min prior to the injection of 99m TcCCMSH. For the imaging study, each mouse was given 25 mCi of 99m TcCCMSH by tail-vein injection. The mice were sacrificed 30 min postinjection, and the images were acquired by a Prism XP3000 triple-head ␥ camera (Picker, Cleveland) equipped with a low-energy highresolution parallel collimator. The images were collected on a 512 matrix with ϫ3.999 magnification.
RESULTS AND DISCUSSION
Metal-Binding Site Design. Molecular modeling was used to design and evaluate cyclic ␣-MSH analogs for their potential to incorporate Re or Tc into their structures. Several different factors were taken into account in the design of Re-and Tc-binding sites, including metal coordination geometry, donor-atom selection, and peptide conformation. Both Tc and Re, when in the ϩ5 oxidation state, prefer a similar square pyramidal coordination geometry. Structural studies of small organic complexes of these metals have shown that donor atoms are located at the corners of a square plane, with a monooxo group located above, at the apex of a square pyramid (32) (33) (34) . Another determinant of the metal-binding site was the known preference of these metals for specific donor atoms (i.e., SϾNϾ ϾO) (8) . A third important factor was determined not by the metal, but by the structure of the peptide itself. The metal-binding site must be engineered so that metal coordination does not disrupt the biologically active conformation of the molecule. The cyclic ␣-MSH analog (Cys 4, 10 , D-Phe 7 )-␣-MSH 4-13 (APOMSH) was used as the starting point of our studies (24) . APOMSH retains a core sequence of residues, His-D-Phe-Arg-Trp that has been found to be sufficient for the bioactivity of ␣-MSH (17). It was reported that cyclization and incorporation of a D-amino acid in position 7 both increased the potency and prolonged the biological effect of this analog relative to wild-type ␣-MSH (24) .
Initial Rhenium Complexation. TcMSH complex had an even shorter half-life, with a t 1͞2 of less than 2 hr, consistent with an increased lability of Tc to substitution reactions.
The effect of metal incorporation on the receptor-binding affinity of ReMSH is shown in Table 2 . Receptor-binding assays were performed with APOMSH and ReMSH on B16-F1 murine melanoma cells. A decrease was observed in the ability of the ReMSH analog to displace an 125 I-labeled ␣-MSH analog from the cells in a competitive receptor-binding assay ( Table 2 ). The K i for the ReMSH complex was 6.6 ϫ 10 Ϫ8 , which reflected an apparent receptor binding affinity reduction to 1͞100 that of APOMSH (K i ϭ 6.8 ϫ 10
Ϫ10
). Therefore, it appeared that the presence of the Re(V)O core or its effect on the solution structure of ReMSH significantly reduced the molecule's receptor affinity.
Metal-Binding Site Redesign. Two different approaches were followed to create Re⅐MSH conjugates with improved receptor-binding and bioactivity profiles. Structural information relating to ReMSH indicated that the metal-binding site was too close to residues essential for receptor binding. In one attempt to distance the metal-binding site from the His-DPhe-Arg-Trp core sequence, a spacer Gly residue was inserted between the Trp residue and the C-terminal Cys. It was hypothesized that the addition of the Gly residue would displace the crucial Trp residue from the metal-coordination sphere. The compound was synthesized by using the same conditions used for the synthesis of ReMSH and resulted in a complex that appeared by mass spectroscopy to contain two Re-oxo groups per peptide molecule. Receptor-binding data on this 2:1 Re⅐peptide complex showed no increase in binding affinity over ReMSH (data not shown). That this dimeric complex was the major product of two separate syntheses suggested that there may be an entropic barrier to the cyclization of larger rings via an Re(V)O core.
The second approach used to generate a Re⅐MSH complex with increased receptor-binding affinity involved the synthesis of an analog of APOMSH that contained an additional N-terminal Cys residue, termed Cys-3. It was hypothesized that inclusion of this additional thiolate would drive the metalcoordination sphere away from the His-D-Phe-Arg-Trp core sequence by taking advantage of the increased affinity of Re Compounds were identified based on reverse-phase HPLC coelution with characterized nonradioactive standards. Serum studies were performed at 37°C. ND, value not determined; DTPA, diethylenetriaminopentacetic acid.
and Tc for sulfur donor atoms over nitrogen. NMR characterization of this ReCCMSH complex indicated that only a single amide proton resonance had been lost on Re complexation. The single amide 1 H resonance lost in ReCCMSH was assigned to Cys-4. Ellman's analysis of ReCCMSH revealed no free thiols present in the peptide⅐metal complex, suggesting that, as with ReMSH, all thiolates were involved in metal coordination. Mass spectroscopy confirmed the expected molecular weight of a 1:1 peptide͞metal complex [m͞z (MϩH) ϩ observed ϭ 1648.1, calculated ϭ 1647.9]. In this case, the two N-terminal Cys thiolates, in combination with the intervening amide nitrogen, formed three corners of a square plane. The final donor atom was the remaining Cys-10 thiolate, resulting in cyclization of the molecule. ReCCMSH was also a tricyclic molecule, with rings of 6, 5, and 24 members, respectively (Fig.  1) . Increasing the size of the loop containing the core receptorbinding sequence of ReCCMSH by six atoms was designed to relieve the steric stress apparent in the ReMSH molecule. The structural stability of the ReCCMSH molecule was superior to ReMSH. No degradation of the ReCCMSH molecule was observed by NMR over a 3-wk period. Ellman's analysis of the ReCCMSH NMR sample revealed no detectable free thiols, indicating that three cysteine sulfurs remained coordinated to the ReO core.
The 99m Re-labeled analogs of ReCCMSH were virtually inert to substitution in 10 mM Cys competition assays, whereas the 99m Tc-and 188 Re-labeled analogs of ReMSH were readily exchanged under the same assay conditions (Table 1 ). In addition, both 99m ReCCMSH were stable to 10 mM DTPA and incubation in serum at 37°C. The increased stability of ReCCMSH probably resulted from the presence of an additional sulfur donor atom and from decreased backbone strain in the molecule because of the increased ring size. The receptor-binding affinity of ReCCMSH was more than twice that of CCMSH and greatly improved relative to ReMSH ( Table 2) . Cyclization of CCMSH via metal coordination resulted in a molecule with receptor-binding properties superior to the linear apoCCMSH peptide. The ReCCMSH analog exhibited a dissociation constant of 2.9 nM, approximately 1͞25 that of ReMSH. Redesign of the metal-coordination site in ReCCMSH appeared to relieve unfavorable constraints within the core receptor-binding sequence, while enhancing the molecule's radiochemical stability and receptor-binding affinity.
In Vivo Biodistribution and Imaging. Biodistribution and tumor-targeting properties of 99m TcCCMSH were examined in normal and melanoma-bearing C57BL͞6 mice. The 99m TcCCMSH analog showed rapid clearance from healthy mice, with the kidneys acting as primary route of excretion (data not shown). In melanoma-bearing mice, the TcCCMSH reduced tumor uptake from an average of 8.5% injected dose to 0.82% injected dose at the 30-min time point, confirming receptor-mediated uptake in these tissues. Low activity levels present in the stomachs (Table 4 ) of mice at all time points were consistent with the 99m TcCCMSH complex remaining intact (35) . TcCCMSH was cleared rapidly from the tumor-bearing animals with greater than 60 Ϯ 1.89% of the injected dose present in the urine at 30 min (Table 4 ). There Reported values Ϯ SD (n ϭ 5). was some kidney retention that represented 6.33 Ϯ 0.47% of the injected dose at 30 min and 5.07 Ϯ 0.50% at 60 min postinjection. It is likely that the presence of two positive charges in the CCMSH analog, Arg-8 and Lys-11, contributed to the nonspecific kidney retention (36) . Administration of free lysine before the radiolabeled peptide complex may be effective in reducing kidney retention of the positively charged peptides (37) . A 99m Tc-labeled bombesin peptide analog was also injected into melanoma-bearing mice as a control for nonspecific tumor uptake. The 99m Tc-bombesin analog did not display significant tumor uptake, with levels of 0.71 Ϯ 0.33% dose per gram at 30 min and 0.43 Ϯ 0.22% dose per gram at 60 min postinjection. A tumor-imaging study was performed on a melanomabearing C57BL͞6 mouse. Twenty-five millicuries of 99m TcCCMSH was injected into the tail vein of a mouse bearing a 400-mg melanoma tumor in the right flank. Anterior and lateral scintigraphic images of the mouse were acquired 30 min postinjection. The imaging results were consistent with the biodistribution data. Significant accumulation of the 99m Tc-labeled peptide was clearly visible in the melanoma tumor (Fig. 2) . Radioactivity was also present in the kidneys and bladder, which serve as the primary route for peptide excretion. These results demonstrated that the redesigned 
CONCLUSION
We have demonstrated the application of structure-based molecular design in the development of ␣-MSH receptor-avid peptides that were cyclized through the coordination of the transition metals Re and Tc. Several cycles of peptide design, synthesis, structural analysis, and functional characterization were employed to develop ␣-MSH analogs that incorporated Re and Tc into their structures while retaining high affinity for their cognate receptors present on melanoma cells. The ability of the 99m TcCCMSH analog to target melanoma in a murinetumor model system demonstrated the potential use of these compounds for melanoma imaging or therapy.
